EN
TR
The relationship between paraoxonase, arylesterase, lipoprotein (a) and other lipid parameters in patients with coronary heart disease
Abstract
Objective: Millions of people die every year in industrialized countries due to coronary heart disease (CHD) and rank first among the causes of mortality. It is vital to know the causes of CHD and to determine early diagnosis methods. Low antioxidant enzyme paraoxonase (PONl) activity in High Density Lipoprotein (HDL) structure, which prevents Low Density Lipoprotein (LDL) oxidation, is a risk factor for CHD.
Method: For this purpose, serum PONl activities, ARE activities, Lp (a), apo A, apo B and other lipid parameters were investigated in 80 patients who were diagnosed with CHD who applied to the Cardiology Clinic of Fırat University Medical Faculty Hospital. CHD group; It consists of coronary heart patients who have undergone myocardial infarction to the cardiology outpatient clinic, or who have decided to by-pass operation as a result of coronary angiography, who use antiischemic drugs, have no diabetes, do not drink alcohol and smoke, do not have coronary heart disease in the family history, do not take lipid-lowering drugs. The control group consists of 40 healthy individuals without cardiovascular disease, diabetes or a disease affecting serum lipid level.
Results: Cholesterol, triglyceride (TG), HDL, LDL, VLDL, serum PONl and ARE activities, Lp (a), apo A and apo B levels were found statistically significant in the CHD compared to the healthy control group (p <0.05). Serum PONl activity and ARE activity were lower in the patient groups compared to the healthy control group, and serum Lp (a) levels were higher (p <0.05).
Conclusions: Serum PONI activity serum Lp (a) levels, which are accepted as important parameters in the diagnosis of CHD, were also found to be significant biochemical markers in our study.
Keywords
Destekleyen Kurum
Fırat Üniversitesi Araştırma Fonu (FÜNAF-514)
Proje Numarası
FÜNAF-514
Kaynakça
- 1. Özkan S, Yılmaz ÖÇ. The relationship between metabolic syndrome score and cardiac ischemia detected by noninvasive cardiac tests. Cumhuriyet Medical Journal. 2020; 42(1): 44-48.
- 2. Martinez LG, Bucher L. Coronary Artery Disease and Acute Coronary Syndrome, Medical Surgical Nursing, Discover Books, USA. 2005; 784-785.
- 3. Badır A, Korkmaz FD. Koroner Arter Hastalıkları, Dahili ve Cerrahi Hastalıklarda Bakım, Üçüncü Baskı, İstanbul, Akademisyen Kitapevi. 2014; 431-445.
- 4. ESC Klavuzları, Avrupa Klinik Uygulamada Kardiyovasküler Hastalıklardan Korunma Klavuzu.Türk Kardiyoloji Derneği Arşivi. 2012; 40: 126-128.
- 5. Montalestcot G. ESC Kararlı Koroner Arter Hastalığı Yönetimi Kılavuzu. Türk Kardiyoloji Derneği Araştırma. 2014; 6: 96-100.
- 6. Forrester JS, Merz NB, Bush L. Task force fourth efficacy of risk factor management. JACC. 1996; 27: 991-1006.
- 7. Hamm WC. Israrcı ST Segment Yükselmesi Belirtileri Göstermeyen Hastalarda Akut Koroner Sendromların Tedavi Kılavuzları. Türk Kardiyoloji Derneği Arşivi. 2011; 39(3): 73-128.
- 8. World Health Organisation (WHO). The 10 leading causes of death in the world, 2000-2012, http:// www.who.int/ mediacentre/ factssheets/ fs310/en/, [10.10.2017]
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
27 Ekim 2020
Gönderilme Tarihi
8 Temmuz 2020
Kabul Tarihi
21 Eylül 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 42 Sayı: 3